Biocept Expands Intellectual Property Portfolio with 12th Granted Patent on its Key Liquid Biopsy Technology
"With the issuance of this patent, we have now completed our patent portfolio to include all key components central to our Cell Enrichment and Extraction (CEE™) platform for the transport, capture, enrichment, identification and analysis of CTCs from blood samples and other biological fluids," said
The newly issued patent covers a staining method employed in the CEE platform that provides for the high-efficiency capture, visualization and microscopic analysis of targeted cells that are obtained from biofluid samples. This patent interfaces well with
"We have been aggressively broadening our IP protection for our unique methods of capturing and analyzing cancer cells in blood and other biological fluids," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the detection and treatment of cancer, our ability to capitalize on the
growing movement toward the use of liquid biopsy, and our impact on diagnostic strategies and healthcare costs, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-expands-intellectual-property-portfolio-with-12th-granted-patent-on-its-key-liquid-biopsy-technology-300267123.html
SOURCE
News Provided by Acquire Media